Royalty Pharma plc Class A Ordinary Shares (RPRX)
Royalty Pharma plc Class A Ordinary Shares
XNAS:RPRX
40.02
$40.24 - 99.00
$39.87 - 99.00
$39.65
$40.07
$39.83
$39.84
41.24
24.05
1612237
3684584.2
336892311.22
Chart
TendieTensor AI Analysis
Company
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Fundamentals
99
22.884263
2.676760
1.17
2.173913
100
432.29M
427.25M
Technicals
Short Interest
—
—
—
Higher = harder to cover
—
Prev: —
—
—
5D avg: —
—
Discussion
Login to participate in discussions.
Recent News
Related Stocks
Based on the portfolios of people who own RPRX. This is a list generated by trading data from 3rd party trading platforms, and it's not a recommendation.